Latest Board Appointment News

Odessa Minerals reports significant progress in uranium exploration at its Lyndon Project, highlighting multiple mineralisation types and upcoming field activities. The company also announces key board changes, positioning itself for strategic growth.

Talius Group reported a solid March quarter with rising revenue, a strategic partnership with Lifestyle SA, and the rollout of its proprietary RTLS software, signaling strong momentum in aged care technology.

Catalina Resources has completed its acquisition of the Central Yilgarn Project, unveiling multiple high-grade gold and silver targets, while securing $2.77 million through placement and rights issues to accelerate exploration.

Mineral Resources Limited reported a steady Q3 FY25 with operational progress at Onslow Iron and lithium assets, alongside ongoing corporate governance reforms and robust financial health.

AUCyber Limited has announced a significant reshuffle of its leadership team, appointing Chris Wright as CEO and welcoming three new non-executive directors, signaling a strategic pivot for the cyber security firm.

Bell Financial Group reported a robust 26.4% increase in profit after tax to $30.7 million for 2024, underpinned by strong performances across all divisions and a declared fully franked final dividend of 4.0 cents per share. The Group is actively pursuing growth through acquisitions and strategic account transfers, positioning itself for a cautiously optimistic 2025.

Noble Helium Limited has announced a sweeping board and executive reshuffle following pressure from major shareholders, signaling a strategic reset aimed at strengthening its financial footing and advancing its Tanzanian helium projects.

Trigg Minerals has secured NSW Government approval for the transfer of its Achilles Project licence, enabling formal exploration of the high-grade Wild Cattle Creek antimony deposit.

DMC Mining Limited progresses its strategic acquisition of the Firawa and Labé uranium projects in Guinea, while navigating key board appointments and capital raising efforts ahead of ASX re-admission.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

Voltaic Strategic Resources reports significant gold and poly-metallic mineralisation at its Kooline and Meekatharra projects, alongside a strategic board restructure and a robust cash position of $5.4 million.

Lykos Metals Limited reports significant high-grade mineral findings at its Sinjakovo Project and extends its Jezero exploration permit, alongside key board appointments and cost restructuring.